|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pemayun TG: Current diagnosis and
management of thyroid nodules. Acta Med Indones. 48:247–257.
2016.PubMed/NCBI
|
|
3
|
Liu S, Semenciw R, Ugnat AM and Mao Y:
Increasing thyroid cancer incidence in Canada, 1970–1996: Time
trends and age-period-cohort effects. Br J Cancer. 85:1335–1339.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valinezhad Orang A, Safaralizadeh R and
Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation
from common downregulation to mRNA-specific upregulation. Int J
Genomics. 2014:9706072014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer. 96
Suppl:R40–R44. 2007.PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261.
2006; View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de la Chapelle A and Jazdzewski K:
MicroRNAs in thyroid cancer. J Clin Endocrinol Metab. 96:3326–3336.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leonardi GC, Candido S, Carbone M,
Colaianni V, Garozzo SF, Cinà D and Libra M: microRNAs and thyroid
cancer: Biological and clinical significance (Review). Int J Mol
Med. 30:991–999. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiping Z, Ming F, Lixiang W, Xiuming L,
Yuqun S, Han Y, Zhifang L, Yundong S, Shili L, Chunyan C, et al:
MicroRNA-212 inhibits proliferation of gastric cancer by directly
repressing retinoblastoma binding protein 2. J Cell Biochem.
114:2666–2672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tu H, Wei G, Cai Q, Chen X, Sun Z, Cheng
C, Zhang L, Feng Y, Zhou H, Zhou B, et al: MicroRNA-212 inhibits
hepatocellular carcinoma cell proliferation and induces apoptosis
by targeting FOXA1. Onco Targets Ther. 8:2227–2235. 2015.PubMed/NCBI
|
|
13
|
Hanieh H: Aryl hydrocarbon
receptor-microRNA-212/132 axis in human breast cancer suppresses
metastasis by targeting SOX4. Mol Cancer. 14:1722015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang X, Chen X, Chen L, Ma Y, Zhou L, Qi
Q, Liu Y, Zhang S, Luo J and Zhou X: Upregulation of the
miR-212/132 cluster suppresses proliferation of human lung cancer
cells. Oncol Rep. 33:705–712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei LQ, Liang HT, Qin DC, Jin HF, Zhao Y
and She MC: MiR-212 exerts suppressive effect on SKOV3 ovarian
cancer cells through targeting HBEGF. Tumour Biol. 35:12427–12434.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou C, Tan DM, Chen L, Xu XY, Sun CC,
Zong LJ, Han S and Zhang YZ: Effect of miR-212 targeting TCF7L2 on
the proliferation and metastasis of cervical cancer. Eur Rev Med
Pharmacol Sci. 21:219–226. 2017.PubMed/NCBI
|
|
17
|
Zhang S, Zhang D, Yi C, Wang Y, Wang H and
Wang J: MicroRNA-22 functions as a tumor suppressor by targeting
SIRT1 in renal cell carcinoma. Oncol Rep. 35:559–567. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tomasetti M, Amati M, Santarelli L and
Neuzil J: MicroRNA in metabolic re-programming and their role in
tumorigenesis. Int J Mol Sci. 17:172016. View Article : Google Scholar
|
|
19
|
Fu W, Tao T, Qi M, Wang L, Hu J, Li X,
Xing N, Du R and Han B: MicroRNA-132/212 upregulation inhibits
TGF-β-mediated epithelial-mesenchymal transition of prostate cancer
cells by targeting SOX4. Prostate. 76:1560–1570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao JL, Zhang L, Guo X, Wang JH, Zhou W,
Liu M, Li X and Tang H: miR-212/132 downregulates SMAD2 expression
to suppress the G1/S phase transition of the cell cycle and the
epithelial to mesenchymal transition in cervical cancer cells.
IUBMB Life. 67:380–394. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H,
Wang W, Huang X, Yuan Z and Ai K: miR-212 promotes pancreatic
cancer cell growth and invasion by targeting the hedgehog signaling
pathway receptor patched-1. J Exp Clin Cancer Res. 33:542014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kinose Y, Sawada K, Nakamura K and Kimura
T: The role of microRNAs in ovarian cancer. BioMed Res Int.
2014:2493932014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Correia M, Perestrelo T, Rodrigues AS,
Ribeiro MF, Pereira SL, Sousa MI and Ramalho-Santos J: Sirtuins in
metabolism, stemness and differentiation. Biochim Biophys Acta.
1861:3444–3455. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herranz D, Maraver A, Cañamero M,
Gómez-López G, Inglada-Pérez L, Robledo M, Castelblanco E,
Matias-Guiu X and Serrano M: SIRT1 promotes thyroid carcinogenesis
driven by PTEN deficiency. Oncogene. 32:4052–4056. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deng CX: SIRT1, is it a tumor promoter or
tumor suppressor? Int J Biol Sci. 5:147–152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Palmirotta R, Cives M, Della-Morte D,
Capuani B, Lauro D, Guadagni F and Silvestris F: Sirtuins and
cancer: Role in the epithelial-mesenchymal transition. Oxid Med
Cell Longev. 2016:30314592016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu W, Zhang L, Lin J, Huang H, Shi B, Lin
X, Huang Z, Wang C, Qiu J and Wei X: Hypermethylation of the HIC1
promoter and aberrant expression of HIC1/SIRT1 contribute to the
development of thyroid papillary carcinoma. Oncotarget.
7:84416–84427. 2016.PubMed/NCBI
|
|
28
|
Ramalinga M, Roy A, Srivastava A,
Bhattarai A, Harish V, Suy S, Collins S and Kumar D: MicroRNA-212
negatively regulates starvation induced autophagy in prostate
cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis
and cellular senescence. Oncotarget. 6:34446–34457. 2015.PubMed/NCBI
|
